Tuesday, January 8th: 2:15PM – 3:10PM

This session features three CEO’s currently involved with companies that are commercialized in Europe. This interactive roundtable is designed to cover main themes for product growth in Europe, as well as analysis of particular key developmental milestones. Topics explored include:

Strategy:
Why Europe today — Market Expectations, and how to navigate cost, time and resources

Financial:
Creative Funding, the Best use of resources in today’s market, and realistic objectives

Regulatory:
Clinical trials, Key opinion leaders, geography, and time to market

Reimbursement:
Where and when, time savers, and navigating the system

The workshop will also explore reaching short-term milestones upon commercialization, including:

• Shotgun or rifle approach?
• Direct vs. Distributor
• Partnership opportunities

Faculty:

Rick Hughes, President, HealthLink Europe, has been in the medical device industry for 18 years, and joined HealthLink Europe in February 2005. During the first year of his tenure, HealthLink Europe secured funding from a private investment firm, opened a North American Office, and invested in top quality management and IT systems, to support the future growth of the company. Mr. Hughes became President of HealthLink Europe in December 2005 and since then the company has grown significantly each year providing operational support for more than 50 medical device manufacturers in Europe. Before joining HealthLink Europe, Mr. Hughes was Vice President of Client Development for TriVirix, an FDA registered contract manufacturer of electronic and electro- mechanical medical devices, from February 2000, to January 2005. During this time TriVirix achieved rapid annual growth, supporting medical device manufacturers in America and the UK. Prior to joining TriVirix, Mr. Hughes spent six years with Vernacare, a UK based hospital equipment and disposables manufacturer, where he became an Account Director in North America. Mr. Hughes holds a Bachelor of Arts degree from Oxford Brookes University in the UK.

Gibb Clarke, co-founder and CEO of Blockade Medical, has more than 10 years experience as a medical device executive with a specific focus on new technology development for the interventional neurovascular marketplace. Prior to co-founding Blockade, Gibb co-founded Pulsar Vascular, Inc. in 2006. A novel therapeutic approach for challenging and complex cerebral aneurysms. Gibb successfully raised multiple rounds of venture capital as well as helped craft and manage the clinical and regulatory strategy for both CE Mark and US approvals. Prior to Pulsar, Gibb played a critical early role in helping Swedish Medical Center in Seattle, WA, plan for and execute the development of The Seattle Neuroscience Institute, a neuroscience center for excellence. Gibb’s efforts resulted in Swedish Medical investing in excess of $35M into the development of its now flagship neuroscience center located in Seattle, WA. Gibb also spent 8 years in the US Marines Corps serving as a team leader in the elite Marine Recon unit. Military schoolings include Amphibious Recon Course, Army Ranger School, US Navy Dive School, and Army Jump School. Gibb is an avid endurance athlete, having competed in over 200 races.

Greg Lambrecht, Founder and Executive Director of Intrinsic Therapeutics, Inc, a venture-backed medical device company focused on addressing the needs of patients with spinal disorders. Mr. Lambrecht is also founder and board member of Viacor, Inc., a start-up medical device company, and Coravin, LLC, a consumer product company, both in the Boston area. Prior to this, Mr. Lambrecht was Vice President of Product Development & Marketing at Stryker, a global orthopedic implant company where he directed the development and launch of numerous successful orthopedic implants. Mr. Lambrecht also held various management positions in product development, marketing, and business development within Pfizer’s Medical Technology Group. The core of his career at Pfizer was directed at implementing a process for inventing and developing technologies that best met the needs of Pfizer’s physician customers worldwide. Mr. Lambrecht holds a Masters of Science in Mechanical Engineering and a Bachelor of Science in Nuclear Engineering from the Massachusetts Institute of Technology. He holds numerous patents in the fields of gynecology, general surgery, cardiology, and orthopedics.

Paul Geudens, founder and CEO of Quarterback Consulting. Quarterback Consulting’s mission is to provide executive support to US based Cardiovascular Device startups in their (pre)-commercialization into Europe, the latest being Surpass Medical that was recently acquired by Stryker for $135M. Paul is a senior executive holding a unique blend of medical, commercial and business development experience. Paul started his career in ’81 as head of the Department of Interventional Cardiology at the University Hospital of Antwerp, Belgium. In 1988, Paul made the move to the Medical Device industry and held roles of increasing responsibility at Baxter, BOC UK and, from 1997 till 2009, at Cordis Johnson and Johnson. At Cordis, he was responsible for the launch of the company’s blockbuster BMS and DES coronary stents, the development of the Neurovascular business and for their leadership in the highly competitive Endovascular market. In 2009, Paul made his entry into the medical device startup environment as Vice President of Sales and Marketing at Stentys SAS, Paris, France. After 1 year of highly successful commercial activity under Paul’s leadership, the company went into an IPO and raised $31.9M at the NYSE Euronext Paris Stock Exchange. Paul founded Quarterback Consulting early 2012. In his role as Executive Consultant to Surpass Medical, he has been instrumental in creating company value that led to the before mentioned successful acquisition. With Quarterback Consulting, Paul is further developing and refining effective EU commercial entry strategies that apply to a number of current and future Medical Device clients. Paul holds a BSc in Radiography and Hospital Management and an ADP at London Business School.

This workshop, sponsored by Dawson James Securities, set out to create the highest-quality, full service investment firm specializing in the complex and fast-moving healthcare, biotechnology, technology and clean-tech sectors.

Whether you’re an institutional investor seeking expert guidance, a corporation requiring timely financial transactions or an individual investor needing superior service, Dawson James Securities, Inc. aims to deliver.

Learn more about Dawson James Securities

Tuesday, January 11th, 2011

Session 1 – Diagnostics & Personalized Medicine: Advances in molecular biology now make it possible to detect diseases sooner, allowing physicians to advise patients on optimal therapies. This panel explores the changing world of diagnostics, bringing together executives, experienced venture capitalists, and a physician. Together they will explore the product areas and business models that have made diagnostics a hot area for investors today. Along the way, panelists will discuss new technologies of interest to consolidators and address the challenges start-ups face in commercializing these game-changing products.

Panelists:

Session 2 – Neurology: Technological advances continue to give hope that new medical devices will improve the quality of life for people with neurological conditions such as epilepsy or Parkinsons’ Disease. There is also hope that these advances will stimulate better recovery for patients with neurological damage from traumatic events ranging from ischemic stroke to spinal cord injury. This panel, comprised of leading strategic/venture investors and industry veterans, will explore the most appealing therapeutic areas and technologies for investment in 2011. Panelists will discuss what it takes for a neurology-related company to succeed in today’s challenging economic and regulatory climate.

Panelists:
Denise Barbut, MD, Founder Benechill
Frank Fischer, President, Neuropace, Inc.
Mike Henson, General Partner, Medfocus Fund
Jeff Erb, Director Business Development, Medtronic

Session 3 – Urology and Womens Care: Urology and Women’s health have been areas of substantial M&A activity during the last 10 years as the major medtech consolidators have been busy building separate business units to address these medical needs. This panel includes representatives from several large medtech acquirers, as well as venture and private equity firms with major investments in this field. The panelists will explore exciting new products under development and the issues facing this dynamic market.

Panelists:
Jessica Grossman MD, Ethicon
Jan Garfinkle, Managing Partner, Arboretum Ventures
Ben Daverman, Partner, GTCR Golder Rauner
David Amerson, Global Vice President Coloplast Surgical Urology
Don Haut, Senior Vice President, Smith & Nephew

Wednesday, January 12th, 2011

Session 1 – Cardiology: Advances in structural heart repair/replacement, cardiac rhythm management, interventional techniques, cell replacement and regeneration therapies continue to refine one of the most successful areas of modern medicine: cardiac care. This panel of highly experienced medical and business professionals will describe what important products are on the horizon, and how these products will fare in a post healthcare – reform world.

Panelists:
Frank Litvack, Former President, Conor
Tao Forcht Dagi, MD, Partner, HLM Ventures
David Milne, Partner, SV LifeSciences
Michael Buck, Director Business Development, Abbott Ventures

Session 2 – Orthopedics: The orthopedic market include joint reconstruction, spine, trauma fixation, arthroscopy and biologics. Growth in each of these sectors is being driven by an aging US population. Today there are a large number of very innovative solutions in development which should offer the large orthopedic companies an opportunity to grow rapidly during the coming years. Join our panel of experts to explore the products in development and the interest and needs of the potential acquirers.

Panelists:
Bryan Hughes, Director, P & M Corporate Finance
Nancy Lynch, MD
John Barrett, CEO, CoAlign Surgical
Richard Ferrari, Partner, DeNovo Ventures
Karen Talmadge, Vice President Medtronic Inc.

Session 3 – Oncology: Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer. These advanced products include advanced cancer screening and imaging technologies, infusion of therapeutic materials directly into a tumor’s blood vessel, radiotherapy to treat solid tumors throughout the body more accurately and less invasively, as well as stem cell and antibody treatments to fight malignancies. This panel will discuss new products in development, their impact on patient care and the interest of medtech consolidators in these advanced therapies.

Panelists:
Scott Schalk, Managing Director, Dawson James
Daniel Kraft, MD
Euan Thompson, CEO, Accuray
Norm Weldon, Investor
Tom Umbel, Vice President, Hologic